Reducing affinity as a strategy to boost immunomodulatory antibody agonism

[1]  A. Oxenius,et al.  Single B cell technologies for monoclonal antibody discovery. , 2021, Trends in immunology.

[2]  Emma L Henderson,et al.  Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors , 2021, JCI insight.

[3]  M. Cragg,et al.  On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation , 2021, Communications Biology.

[4]  Ashley V. Kroll,et al.  Computational design of a synthetic PD-1 agonist , 2021, Proceedings of the National Academy of Sciences.

[5]  M. Cragg,et al.  TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity , 2021, Communications biology.

[6]  Asher Mullard.  FDA approves 100th monoclonal antibody product , 2021, Nature Reviews Drug Discovery.

[7]  M. Nussenzweig,et al.  Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates , 2020, Cell.

[8]  Lestat R. Ali,et al.  Immune receptor inhibition through enforced phosphatase recruitment , 2020, Nature.

[9]  V. Boussiotis,et al.  Revisiting the PD-1 pathway , 2020, Science Advances.

[10]  M. Cragg,et al.  Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity , 2020, Cancer cell.

[11]  Hsin-Jung Li,et al.  Development of therapeutic antibodies for the treatment of diseases , 2020, Journal of Biomedical Science.

[12]  Mark M. Davis,et al.  Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease , 2020, Nature.

[13]  V. Boussiotis,et al.  Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells , 2019, Scientific Reports.

[14]  W. Wenzel,et al.  Trends in therapeutic antibody affinity maturation: From in-vitro towards next-generation sequencing approaches. , 2019, Immunology letters.

[15]  C. Vollmers,et al.  A simplified workflow for monoclonal antibody sequencing , 2019, PloS one.

[16]  A. Nager,et al.  Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab , 2018, Nature Communications.

[17]  R. Cornall,et al.  Immune Checkpoints as Therapeutic Targets in Autoimmunity , 2018, Front. Immunol..

[18]  A. Hoos,et al.  The promise and challenges of immune agonist antibody development in cancer , 2018, Nature Reviews Drug Discovery.

[19]  M. Cragg,et al.  Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies , 2018, Cancer cell.

[20]  Craig B. Davis,et al.  Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer , 2018, Clinical Cancer Research.

[21]  R. Salgia,et al.  Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations , 2018, Journal of Immunotherapy for Cancer.

[22]  I. Melero,et al.  Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. , 2018, Blood.

[23]  Jaykaran Charan,et al.  Monoclonal Antibodies: A Review. , 2017, Current clinical pharmacology.

[24]  S. Ryu,et al.  Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy , 2016, Nature Communications.

[25]  Rony Dahan,et al.  Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. , 2016, Cancer cell.

[26]  H. Wajant,et al.  Principles of antibody-mediated TNF receptor activation , 2015, Cell Death and Differentiation.

[27]  Eugene Krissinel,et al.  Stock-based detection of protein oligomeric states in jsPISA , 2015, Nucleic Acids Res..

[28]  B. Nilsson,et al.  Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. , 2015, Cancer cell.

[29]  M. Cragg,et al.  Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies , 2015, Cancer cell.

[30]  D. Forthal,et al.  Functions of Antibodies , 2014, Microbiology spectrum.

[31]  R. Minter,et al.  A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency , 2012, Cell Death and Differentiation.

[32]  M. Cragg,et al.  Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody , 2011, The Journal of Immunology.

[33]  G. Adams,et al.  Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. , 2011, Cancer research.

[34]  E. Clark,et al.  The role of CD40 and CD154/CD40L in dendritic cells. , 2009, Seminars in immunology.

[35]  K. Henrick,et al.  Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.

[36]  M. Sliwkowski,et al.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. , 2004, Molecular biology of the cell.

[37]  C. June,et al.  SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 , 2004, The Journal of Immunology.

[38]  C. Ahonen,et al.  The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells , 2002, Nature Immunology.

[39]  T. Honjo,et al.  Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme , 2000, Cell.

[40]  M. Kuroki,et al.  Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody. , 1996, Journal of biochemistry.

[41]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[42]  T. Clackson,et al.  Making antibody fragments using phage display libraries , 1991, Nature.

[43]  C. Janeway,et al.  Different phenotypic variants of the mouse B cell tumor A20/2J are selected by antigen- and mitogen-triggered cytotoxicity of L3T4-positive, I-A-restricted T cell clones. , 1986, Journal of immunology.

[44]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.